Example: Heart Attack

Clinical Trials on Lipogranulomatosis

Total 18 results

    • NCT03329274
      Recruiting
      Registry for Patients With Erdheim-Chester Disease
      Conditions: Erdheim-Chester Disease
    • NCT01727206
      Terminated
      Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease
      Conditions: Erdheim-Chester Disease
    • NCT03794297
      Recruiting
      Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
      Conditions: Erdheim-Chester Disease
    • NCT02089724
      Unknown status
      Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
      Conditions: Erdheim-Chester Disease
    • NCT03990428
      Recruiting
      Supportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic Diseases
      Conditions: Supportive Care Needs of Caregivers
    • NCT02281760
      Completed
      Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
      Conditions: BRAF V600E Mutation
    • NCT01417520
      Completed
      Clinical and Pathophysiological Investigations Into Erdheim Chester Disease
      Conditions: Myelofibrosis; Gaucher Disease; Pulmonary Fibrosis; Hermansky-Pudlak Syndrome (HPS); Cancer
    • NCT02298634
      Active, not recruiting
      Biomarker for Farber Disease (BioFarber)
      Conditions: Farber's Lipogranulomatosis; Ceramidase Deficiency; Hepatomegaly; Splenomegaly
    • NCT04158284
      Recruiting
      Multicenter Registry for Patients With Childhood.Onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts
      Conditions: Craniopharyngioma; Obesity
    • NCT02608619
      Completed
      Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
      Conditions: Erdheim-Chester Disease; Langerhans Cell Histiocytosis; Histiocytic Disorders
    • NCT03233841
      Completed
      Farber Disease Natural History Study
      Conditions: Farber Disease; Farber's Disease; Farber Lipogranulomatosis; Acid Ceramidase Deficiency; Ceramidase Deficiency; N-Laurylsphingosine Deacylase Deficiency; ASAH1 Mutation
    • NCT02523040
      Active, not recruiting
      A Study of Lenalidomide for Adult Histiocyte Disorders
      Conditions: Langerhans Cell Histiocytosis (LCH); Histiocytoses Erdheim-chester Disease; Histiocytic Sarcoma (HS)
    • NCT04198818
      Recruiting
      A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
      Conditions: Advanced Tumors; Melanoma; Non-Small-Cell Lung Cancer; Erdheim-Chester Disease; Other RAS/RAF/MEK/ERK Mutated Tumors
    • NCT03127709
      Recruiting
      A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis
      Conditions: Histiocytosis
    • NCT02285582
      Recruiting
      International Rare Histiocytic Disorders Registry (IRHDR)
      Conditions: Rare Histiocytic Disorders (RHDs); Juvenile Xanthogranuloma (JXG); Reticulohistiocytoma (Epithelioid Histiocytoma); Xanthoma Disseminatum (XD); Multicentric Reticulohistiocytosis (MRH); Systemic Juvenile Xanthogranuloma; Erdheim-Chester Disease (ECD); Multi-system Rosai-Dorfman Disease (RDD)
    • NCT04079179
      Not yet recruiting
      Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
      Conditions: Langerhan's Cell Histiocytosis; Juvenile Xanthogranuloma; Erdheim-Chester Disease; Rosai Dorfman Disease; Neuro-Degenerative Disease; Histiocytic Sarcoma; Histiocytic Disorders, Malignant
    • NCT01552434
      Recruiting
      Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
      Conditions: Advanced Malignant Neoplasm; Castleman Disease; Digestive System Carcinoma; Erdheim-Chester Disease; Lip and Oral Cavity Carcinoma; Lymphangioleiomyomatosis; Malignant Endocrine Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Male Reproductive System Neoplasm; Malignant Neoplasm; Malignant Respiratory Tract Neoplasm; Malignant Thoracic Neoplasm; Malignant Urinary System Neoplasm; Mesothelial Neoplasm; Metastatic Malignant Neoplasm; Metastatic Urothelial Carcinoma; Neurofibromatosis Type 2; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Digestive System Carcinoma; Recurrent Female Reproductive System Carcinoma; Recurrent Male Reproductive System Carcinoma; Recurrent Malignant Neoplasm; Recurrent Pharyngeal Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Malignant Neoplasm; Soft Tissue Neoplasm; Stage III Breast Cancer AJCC v7; Stage III Pharyngeal Cancer; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Pharyngeal Cancer; Stage IVA Pharyngeal Cancer; Stage IVB Pharyngeal Cancer; Stage IVC Pharyngeal Cancer; Thyroid Gland Neoplasm
    • NCT03155620
      Recruiting
      Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
      Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations